Zobrazeno 1 - 10
of 84
pro vyhledávání: '"M J, Egorin"'
Autor:
J Z, Kerr, S L, Berg, R, Dauser, J, Nuchtern, M J, Egorin, L, McGuffey, A, Aleksic, S, Blaney
Publikováno v:
Cancer Chemotherapy and Pharmacology. 47:411-414
Gemcitabine (dFdC) is a difluorine-substituted deoxycytidine analogue that has demonstrated antitumor activity against both leukemias and solid tumors. Pharmacokinetic studies of gemcitabine have been performed in both adults and children but to date
Autor:
Michael Glantz, C. M. Kearns, Pam Mills, Bernard F. Cole, E. G. Zuhowski, Hak Choy, Stephen Saris, Edward G. Stopa, C. H. Rhodes, M. J. Egorin
Publikováno v:
Journal of Clinical Oncology. 14:600-609
PURPOSE Astrocytomas are extremely resistant to currently available treatments. Cranial irradiation is a mainstay of frontline therapy, but tumor recurrence is nearly universal. Paclitaxel has shown antitumor efficacy against astrocytoma cell lines,
Publikováno v:
Cancer Chemotherapy and Pharmacology. 35:254-256
Autor:
A H, Calvert, M J, Egorin
Publikováno v:
European journal of cancer (Oxford, England : 1990). 38(1)
Autor:
W C, Zamboni, D Z, D'Argenio, C F, Stewart, T, MacVittie, B J, Delauter, A M, Farese, D M, Potter, N M, Kubat, D, Tubergen, M J, Egorin
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(8)
Pharmacodynamic measures of neutropenia, such as absolute neutrophil count at nadir and neutrophil survival fraction, may not reflect the overall time course of neutropenia. We developed a pharmacokinetic-pharmacodynamic model to describe and quantif
Autor:
David I. Rosenthal, Eugene P. Frenkel, M. J. Egorin, D. M. Rosen, Ara A. Chalian, D. A. Yardley, Linda Miller, Jason H. Lee, R. J. Sinard, Gregory S. Weinstein, D. P. Carbone, Mitchell Machtay, R.S. Weber
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(5)
PURPOSE: Paclitaxel is one of the most active agents for squamous cell carcinoma of the head and neck (SCCHN) and an in vitro radiosensitizer. The dose-response relationship for paclitaxel may depend more on exposure duration than on peak concentrati
Autor:
J R, Murren, S A, DiStasio, A, Lorico, A, McKeon, E G, Zuhowski, M J, Egorin, A C, Sartorelli, G, Rappa
Publikováno v:
Cancer journal (Sudbury, Mass.). 6(4)
The coumarin antibiotic novobiocin potentiates the activity of etoposide (VP-16) in vitro by increasing intracellular accumulation of VP-16. The drug efflux pump inhibited by novobiocin appears to be distinct from both of the major proteins associate
Publikováno v:
Thyroid : official journal of the American Thyroid Association. 10(7)
Anaplastic thyroid carcinoma is a rare, lethal disease with no effective systemic therapies. Preclinical studies demonstrated antineoplastic activity of paclitaxel. This prompted a prospective phase 2 clinical trial to determine activity of paclitaxe
Autor:
P M, Fracasso, P, Westervelt, C L, Fears, D M, Rosen, E G, Zuhowski, L A, Cazenave, M, Litchman, M J, Egorin, P, Westerveldt, C A, Fears
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 18(5)
PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of paclitaxel when given with PSC 833 (valspodar) to patients with refractory solid tumors. PATIENTS AND METHODS: Patients were initially treat
Autor:
L L, Muldoon, M A, Pagel, R A, Kroll, R E, Brummett, N D, Doolittle, E G, Zuhowski, M J, Egorin, E A, Neuwelt
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(1)
Platinum-based chemotherapeutic agents, such as carboplatin and cisplatin, are effective against many human tumors, but their use may be limited by a high incidence of ototoxicity. Delayed administration of the chemoprotective agent sodium thiosulfat